DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
DarioHealth Corp.NASDAQ: DRIO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $524K fell 58.3% year over year, ahead of the -71.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 130.8% from the prior quarter. Over 3 fiscal years it compounded at -9.0% a year.
Context
- Depreciation & amortization amounted to 15.9% of revenue in FY2025, down 11.5 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -58.3% holds above the trailing-twelve-month pace of -71.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.56M USD
- Year-over-year change
- -52.1%
- 4-year CAGR
- -5.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.56M | -52.1% |
| FY2024 | 2024-12-31 | 7.43M | +49.0% |
| FY2023 | 2023-12-31 | 4.99M | +5.7% |
| FY2022 | 2022-12-31 | 4.72M | +5.8% |
| FY2021 | 2021-12-31 | 4.46M | — |
Depreciation & Amortization vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 depreciation & amortization of $2.1M is the 9th highest of the 11 companies compared; the peer median is $18.93M.
- Its year-over-year change of -71.5% is the 9th highest of 10, against a peer median of -5.9%.
- Depreciation & amortization amounts to 9.9% of revenue for DRIO, versus a peer median of 6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $135.37M | +42.0% | +16.7% | 16.4% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
| LTM Mar 2026 | $39.5M | -9.6% | -11.0% | 5.5% | |
| LTM Mar 2026 | $24.2M | +0.1% | -9.6% | 7.6% | |
| LTM Mar 2026 | $20.17M | -5.9% | +11.9% | 2.1% | |
| LTM Mar 2026 | $17.69M | -95.7% | +207.8% | 11.1% | |
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $11.4M | -12.6% | -3.4% | 620.8% | |
| LTM Mar 2026 | $2.1M | -71.5% | -9.0% | 9.9% | |
| LTM Mar 2026 | $997K | +3223.3% | +83.4% | 2.0% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $0 | — | — | 0.0% |
| Peer median (excluding DRIO) | $18.93M | -5.9% | +6.5% | 6.9% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M |
| Cost of Revenue | 12.44M | 18M | 14.37M | 13.77M | 9.69M |
| Gross Profit | 8.07M | 9.66M | 5.98M | 13.27M | 12.67M |
| Gross Margin | 39.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Research & Development | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M |
| Selling, General & Admin | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M |
| Operating Expenses | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M |
| EBITDA | (70.02M) | (55.6M) | (54.38M) | (37.08M) | (34.69M) |
| EBITDA Margin | -341.3% | -201.0% | -267.2% | -137.1% | -155.2% |
| Operating Income | (76.49M) | (56.81M) | (56.19M) | (57.74M) | (36.66M) |
| Operating Margin | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Interest Income | 44K | 506K | 1.87M | 1.12M | 943K |
| Interest Expense | 84K | 2.68M | 645K | 96K | 3.36M |
| Other Income / Expenses | (235K) | (5.38M) | (3.17M) | 13.15M | (4.95M) |
| Income Before Tax | (76.73M) | (62.19M) | (59.36M) | (44.6M) | (41.61M) |
| Pre-Tax Margin | -374.1% | -224.9% | -291.7% | -164.9% | -186.1% |
| Income Tax Expense | 32K | 4K | 64K | (1.85M) | 105K |
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Net Margin | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (Basic) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| EPS (Diluted) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| Weighted Avg Shares | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
| Weighted Avg Shares (Diluted) | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.